Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 September 2022 | Story Leonie Bolleurs | Photo Johané Odendaal and Edward Lee
UFS Solar car
Team UFS entered the Sasol Solar Challenge for the very first time this year, competing with seven other teams and showcasing their technological input and innovation.

Excitement. Nervousness. A thousand thoughts going through our minds, but primarily “Are we really ready for the challenges that lie ahead?” and “What did we get ourselves into?” In the moments leading up to this year’s Sasol Solar Challenge, these were the thoughts and emotions of Team UFS, who entered their solar car, Lengau.

“But I had confidence in the team,” says Dr Hendrik van Heerden from the UFS Department of Physics at the University of the Free State (UFS) and project manager of Team UFS who entered the challenge for the very first time this year.

Testing perseverance

Entering the Sasol Solar Challenge – a biennial competition that has been running since 2008 – Team UFS competed against seven other teams (representing local and international universities, high schools, and engineering teams), sharing the public roads of South Africa with trucks and regular traffic, sometimes experiencing steep mountain climbs, testing not only their technological input and innovation, but also their perseverance over an eight-day period. 

“One of our main challenges was the long time on the road, to which the heavy weight of the solar car, efficiency of the solar panels, and the effective charging of the battery contributed,” says Dr Van Heerden, stating that these problems were difficult to tackle with the small budget they had. “We, however, stayed positive and was determined to pull through.” 

“We were also open for learning from the other teams, the scrutineers, and observers regarding the mechanical, electrical, and body of competing solar cars. Thus, building knowledge and collaborating is a success we celebrate,” he adds.

In the end it paid off, as Team UFS completed the race, covering a distance of more than 500 km and ending in seventh place overall. The team that finished with the greatest distance covered within the allotted time won the challenge, in this instance the Brunel Solar Team, covering 4 228,2 km.

Dr Van Heerden believes that they did exceptionally well for a debut team, proving themselves against the best. “I am of the opinion that this challenge made us stronger and gave each of us a new perspective on how we should approach life,” he adds.

“As we are all enthusiastic about science and engineering, this challenge inspired us to build towards a future where renewable energy could be an important source of energy in South Africa.”
For a debut team, we did exceptionally well, proving ourselves against the best. – Dr Hendrik van Heerden.

Learning the ropes

The teams left Carnival City in Johannesburg on 9 September 2022 and arrived at the finish line at the V&A Waterfront in Cape Town on Friday 16 September 2022.

Talking about the next race, Dr Van Heerden says he wants to build a better, more effective solar car. “We strive to continuously improve the design, technology, and science going into our car,” he says. 

“For this challenge, we were interested in learning about the mechanical, electrical, and overall body of a solar car. Hence, our solar vehicle was designed well enough to participate and reliable enough to succeed.”

According to him, their focus will shift to competing against the other teams for the next Sasol Solar Challenge. “We will also be more prepared, since we now know what to expect from the challenge. It was our first time participating in the Sasol Solar Challenge, and we’ve learnt so much from the past two weeks – we will carry that forward to the next challenge.

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept